Light-activated drug for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a light-activated drug called ASP-1929 for people with locally advanced pancreatic cancer who have completed chemotherapy before surgery. The drug targets cancer cells and is activated by a special light during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic adenocarcinoma that has not spread to other parts of the body.
- Your cancer is considered locally advanced or borderline resectable.
- You have finished chemotherapy before surgery and are planning to have surgery.
- It has been at least 4 to 10 weeks since your last chemotherapy or radiation.
- Your blood counts and organ function are within certain limits, and you are generally in good health (able to do daily activities).
- You are 18 years or older and not pregnant (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, ASP2138, given before surgery for pancreatic cancer that is still removable. After surgery, you will receive standard chemotherapy. The goal is to see if adding ASP2138 before surgery helps improve outcomes.
This trial tests a new treatment for people with advanced pancreatic cancer that has spread and is not removable by surgery, after standard treatments like chemotherapy no longer work. The goal is to see if this experimental therapy can help shrink tumors or slow the disease.
This trial tests whether giving targeted radiation (SBRT) followed by an experimental immunotherapy drug injected directly into the tumor is safe for people with locally advanced pancreatic cancer. It aims to shrink the tumor and help your immune system fight it.
This trial tests a combination of two chemotherapy drugs (AG) plus an immunotherapy (cadonilimab) and a short course of radiation for people with locally advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this approach helps shrink or control the tumor.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
Hear when a new Pancreatic Cancer Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.